Comprehensive analysis of ERCC3 prognosis value and ceRNA network in AML.

Xiebing BaoYao ChenXiao LouJiahui DuHuijun LiNian LiuZaixiang TangJingsheng HuaWeiqiang GuoSong-Bai Liu

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2022)

This study demonstrated that ERCC3 was overexpressed in AML and that high ERCC3 expression can be considered a biomarker conducive to allo-HSCT in AML patients.

Keyphrases

acute myeloid leukemia
dna repair
end stage renal disease
ejection fraction
newly diagnosed
allogeneic hematopoietic stem cell transplantation
prognostic factors
long non coding rna
dna damage
oxidative stress
patient reported outcomes
acute lymphoblastic leukemia